Biocon Group
February 3, 2021 2021-09-22 7:07Biocon Group
Biocon Group
"Our ability to continuously scale new heights across the biopharmaceutical value chain enables us to realise the promise of future therapeutics." – Dr. Kiran Mazumdar-Shaw, Chairman & Managing Director
Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
Global Presence
Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 85 countries.
Delivering Affordable Innovation
Biocon is driven by its commitment to deliver affordable innovation for patients around the world. Its key innovations include world's first Pichia based recombinant human Insulin provided for patients in over 50 countries, marketed in India as INSUGEN®, insulin analogue Glargine, as BASALOG®. INSUPen® is the next generation German technology based affordable insulin delivery device introduced in India to ensure better compliance and management of diabetes.
Biocon is credited with introducing India's first indigenously developed monoclonal antibody BioMAb-EGFR®, for head & neck cancer in 2006 and has successfully developed and launched in India another Novel biologic Itolizumab, ALZUMAb™ for Psoriasis- a ‘first- in- class’ anti CD6 monoclonal antibody with a potential to address many autoimmune diseases.
Committed to Building Human Capital
The Biocon Academy has been set up by Biocon as an extension of its corporate responsibility for capacity building by developing high end talent that is employable and its commitment to create a globally competitive biotech ecosystem in India.
